North Dakota's rules for which patients get semaglutide and tirzepatide coverage may conflict with drug manufacturers' rebate strategies.

The health insurer appears to be the first big carrier with a business unit president in charge of the cash-for-coverage arrangements.

A key provision in the new legislation could affect compensation for brokers or consultants who help employers hire pharmacy benefit managers.

The bill is similar to Pennsylvania's new law and would curb PBMs by setting rules for rebates, audits and specialty drug designation.

A judge in a Massachusetts state court pointed to concerns about undisclosed product bundling, agent licensing and descriptions of non-insurance products.

Braman Motors' lawyers believe their client is the first ERISA plan sponsor to join a big group of plaintiffs with cases consolidated in New Jersey.

If the new Consumer Financial Protection Bureau regulations lead to more doctors billing patients up front, that could increase demand for worksite health finance benefits.

A compliance specialist thinks state-specific mandates for additional services are making coverage subject to the rules more expensive.